GoAI
Get started
Alignment Healthcare, Inc. logo

Alignment Healthcare, Inc.

ALHC

NASDAQHealthcareMedical - Healthcare Plans

Open in GoAI

Previous close

$13.16

+$0.23 · +1.78%

Aug 21, 4:00 PM ET

ALHC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

78

Undervalued

Momentum

49

Neutral

Sentiment

47

Mixed

Risk resilience

51

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Alignment Healthcare, Inc. is a technology-driven Medicare Advantage provider operating a healthcare platform focused squarely on the consumer. This organization delivers personalized medical services across the United States, primarily for elderly individuals and others requiring specific support, leveraging its suite of Medicare Advantage plans. The company directly owns and operates Medicare Advantage programs in California, North Carolina, and Nevada. Beyond its proprietary offerings, it also orchestrates and furnishes essential healthcare services—including professional, institutional, and supplementary care—for beneficiaries of select plans from unrelated Medicare Advantage Health Maintenance Organizations. Established in 2013, Alignment Healthcare maintains its corporate base in Orange, California.

Industry
Medical - Healthcare Plans
Sector
Healthcare
Headquarters
US
CEO
John E. Kao
Listed since
Mar 26, 2021
Employees
1,849

Market position

Day range

Current $13.16

52-week range

Current $13.16

Open
$13.025
Previous close
$12.93
Volume
2.22M
0.39× average
Average volume
5.7M
Average daily volume
Market cap
2.73B USD
Beta
1.13
Market reference 1
50-day average
$18.727
-29.73% below average
200-day average
$19.0295
-30.84% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
65.96×
P/B (TTM)
10.3×
P/S (TTM)
0.6×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
12.55%
Operating margin
1.20%
Net margin
0.89%

Financial health

Debt / equity
1.25×
Altman Z-score
4.73
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends16%4%-8%-20%Gross margin, FY2021: 11.02%Gross margin, FY2022: 12.85%Gross margin, FY2023: 11.02%Gross margin, FY2024: 10.97%Gross margin, FY2025: 12.37%Operating margin, FY2021: -15.25%Operating margin, FY2022: -8.97%Operating margin, FY2023: -7.01%Operating margin, FY2024: -3.76%Operating margin, FY2025: 0.37%Net margin, FY2021: -16.72%Net margin, FY2022: -10.43%Net margin, FY2023: -8.12%Net margin, FY2024: -4.74%Net margin, FY2025: -0.02%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 11.02%. Gross margin FY2022 12.85%. Gross margin FY2023 11.02%. Gross margin FY2024 10.97%. Gross margin FY2025 12.37%. Operating margin FY2021 -15.25%. Operating margin FY2022 -8.97%. Operating margin FY2023 -7.01%. Operating margin FY2024 -3.76%. Operating margin FY2025 0.37%. Net margin FY2021 -16.72%. Net margin FY2022 -10.43%. Net margin FY2023 -8.12%. Net margin FY2024 -4.74%. Net margin FY2025 -0.02%.

Income trends

Revenue

3.95B USD+46.06%

Operating income

14.75M USD+116.31M USD

Net income

−724K USD+99.43%
Income trends across reported periods4.36B USD2.71B USD1.05B USD−609.69M USDRevenue, FY2021: 1.17B USDRevenue, FY2022: 1.43B USDRevenue, FY2023: 1.82B USDRevenue, FY2024: 2.7B USDRevenue, FY2025: 3.95B USDOperating income, FY2021: −178.07M USDOperating income, FY2022: −128.64M USDOperating income, FY2023: −127.82M USDOperating income, FY2024: −101.56M USDOperating income, FY2025: 14.75M USDNet income, FY2021: −195.29M USDNet income, FY2022: −149.55M USDNet income, FY2023: −148.02M USDNet income, FY2024: −128.04M USDNet income, FY2025: −724K USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.17B USD. Revenue FY2022 1.43B USD. Revenue FY2023 1.82B USD. Revenue FY2024 2.7B USD. Revenue FY2025 3.95B USD. Operating income FY2021 −178.07M USD. Operating income FY2022 −128.64M USD. Operating income FY2023 −127.82M USD. Operating income FY2024 −101.56M USD. Operating income FY2025 14.75M USD. Net income FY2021 −195.29M USD. Net income FY2022 −149.55M USD. Net income FY2023 −148.02M USD. Net income FY2024 −128.04M USD. Net income FY2025 −724K USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.95B USD2.7B USD1.82B USD1.43B USD1.17B USD
Cost of goods sold3.46B USD2.41B USD1.62B USD1.25B USD1.04B USD
Gross profit488.56M USD296.69M USD201.03M USD184.28M USD128.73M USD
Selling, general, and administrative—371.37M USD307.43M USD295.65M USD290.99M USD
Operating expenses473.81M USD398.25M USD328.85M USD312.92M USD306.8M USD
Interest expense15.8M USD23.55M USD21.23M USD18.29M USD17.44M USD
Depreciation and amortization30.48M USD27.06M USD21.67M USD17.49M USD16.03M USD
Operating income14.75M USD−101.56M USD−127.82M USD−128.64M USD−178.07M USD
Net income−724K USD−128.04M USD−148.02M USD−149.55M USD−195.29M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 2 misses, 1 met estimate
Average EPS surprise
+96.11%
11 comparable reports
Latest EPS result
0.17
Estimate 0.13 · Beat by 31.78%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.210.07-0.08-0.22Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.16, estimate -0.18, surprise +11.11%, Beat. Q2 2025, reported May 1, 2025: actual -0.05, estimate -0.12, surprise +58.33%, Beat. Q3 2025, reported Jul 30, 2025: actual 0.07, estimate -0.07, surprise +200.00%, Beat. Q4 2025, reported Oct 30, 2025: actual 0.02, estimate -0.01, surprise +300.00%, Beat. Q1 2026, reported Feb 26, 2026: actual -0.05, estimate -0.15, surprise +66.67%, Beat. Q2 2026, reported Apr 30, 2026: actual 0.05, estimate 0.01, surprise +400.00%, Beat. Q3 2026, reported Jul 30, 2026: actual 0.17, estimate 0.129, surprise +31.78%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate -0.02, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.39B1.13B879.02M624MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 701.24M USD, estimate 677.42M USD, surprise +3.52%, Beat. Q2 2025, reported May 1, 2025: actual 926.93M USD, estimate 888.26M USD, surprise +4.35%, Beat. Q3 2025, reported Jul 30, 2025: actual 1.02B USD, estimate 959.95M USD, surprise +5.76%, Beat. Q4 2025, reported Oct 30, 2025: actual 993.7M USD, estimate 980.9M USD, surprise +1.30%, Beat. Q1 2026, reported Feb 26, 2026: actual 1.01B USD, estimate 1B USD, surprise +0.93%, Beat. Q2 2026, reported Apr 30, 2026: actual 1.24B USD, estimate 1.22B USD, surprise +1.42%, Beat. Q3 2026, reported Jul 30, 2026: actual 1.34B USD, estimate 1.31B USD, surprise +1.96%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 1.31B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

16 ratings
Strong buy00%
Buy1488%
Hold213%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions
KeybancupgradeSector WeightOverweight

ALHC news

globenewswire.com

Kaplan Fox Reminds Investors of Alignment Healthcare, Inc. (NASDAQ: ALHC) of an Ongoing Securities Law Investigation

NEW YORK, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ: ALHC). CLICK…

Read source
newsfilecorp.com

Kaplan Fox Investor Alert: Alignment Healthcare, Inc. (ALHC) Investigated for Possible Securities Law Violations

New York, New York--(Newsfile Corp. - August 21, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or the "Company") (NASDAQ:…

Read source
newsfilecorp.com

Kaplan Fox is Investigating Alignment Healthcare, Inc. (ALHC) and its Board for Possible Securities Law Violations

New York, New York--(Newsfile Corp. - August 20, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or the "Company") (NASDAQ:…

Read source
globenewswire.com

Alignment Healthcare to Present in Baird 2026 Global Healthcare Conference and Attend Morgan Stanley 24th Annual Global Healthcare Conference

ORANGE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will participate in and attend two upcoming healthcare conferences in New York: Presenting: Baird 2026…

Read source
globenewswire.com

Kaplan Fox is Investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) on Behalf of Long-Term Investors

NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ: ALHC). CLICK…

Read source
newsfilecorp.com

Kaplan Fox Notifies Alignment Healthcare, Inc. (ALHC) Investors of a Pending Securities Investigation

New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or the "Company") (NASDAQ:…

Read source

ALHC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ALHC

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
135.42M
Weight
0.12%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
87.82M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
63.55M
Weight
0.03%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
59.32M
Weight
0.07%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
36.83M
Weight
0.08%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
28.29M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
20.79M
Weight
0.14%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares S&P Small-Cap 600 Growth ETF logoiShares S&P Small-Cap 600 Growth ETFIJT
Market value
20.63M
Weight
0.25%
AUM
8.22B USD
Expense ratio
0.18%
Price / 1D
$173.9+0.61%

Continue in GoAI

Research ALHC

research.disclaimer